NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDUpadacitinib Rinvoq®
(15mg, 30mg and 45mg p/r tablets) 		Gastro-intestinal system, Cytokine inhibitors, 01.05.03
REDUpadacitinib RINVOQ®
(15 mg Polonged-release tablets) 		Musculoskeletal and joint diseases, Drugs which suppress the rheumatic disease process, 10.01.03
REDUpadacitinib Rinvoq®
(15mg, 30mg and 45mg p/r tablets) 		Skin, Drugs affecting the immune response, 13.05.03
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Upadacitinib Upadacitinib Gastro-Intestinal System, Chronic Bowel Disorders, Inflammatory Bowel Disease, Immunosuppressants JAK Inhibitors
Upadacitinib Upadacitinib Musculoskeletal System, Arthritis, Immunosuppressants JAK Inhibitors
Upadacitinib Upadacitinib Skin, Inflammatory Skin Conditions, Eczema And Psoriasis, Immunosuppressants JAK Inhibitors
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
NICE TA665: Upadacitinib for treating severe rheumatoid arthritis
NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis
NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
NICE TA829: Upadacitinib for treating active ankylosing spondylitis
NICE TA856: Upadacitinib for treating moderately to severely active ulcerative colitis
NICE TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis
NICE TA905: Upadacitinib for previously treated moderately to severely active Crohn’s disease